Status:
COMPLETED
Association of Platelet Parameters With Bleeding Severity in Children With ITP
Lead Sponsor:
Boston Children's Hospital
Collaborating Sponsors:
Sysmex America, Inc.
Children's Hospital Colorado
Conditions:
Immune Thrombocytopenia
Eligibility:
All Genders
6-20 years
Brief Summary
Patients with severe immune thrombocytopenia (ITP) present with similarly low platelet counts but varying bleeding symptoms, making it difficult to predict the disease course and to decide on an appro...
Detailed Description
Many children with severe immune thrombocytopenia (ITP) present with mild symptoms and their disease spontaneously resolves within 3 to 6 months. However, a subset of pediatric ITP patients experience...
Eligibility Criteria
Inclusion
- Diagnosed with primary or secondary immune thrombocytopenia.
- Platelet count of \< 50 x 10\^9/L
Exclusion
- May not have received aspirin 10 days prior to study entry.
- May not have received nonsteroidal anti-inflammatory drugs (NSAIDs) 3 days prior to study entry.
Key Trial Info
Start Date :
March 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 26 2023
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT03810352
Start Date
March 15 2019
End Date
November 26 2023
Last Update
March 15 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
2
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
3
Columbia University Medical Center
New York, New York, United States, 10032
4
Duke University Medical Center
Durham, North Carolina, United States, 27710